Driving global expansion is essential to the growth strategy at Boston Scientific. We see great opportunity in Emerging Markets1, which represented $1.25 billion in revenue in 2019, or 12 percent of annual sales. We’re continuing to enhance our global reach and strengthen our capabilities in strategically selected Emerging Markets, and expect at least 15 percent growth through 2022 excluding the temporary estimated impact of the COVID-19 pandemic.
- We are globalizing research and development with centers in Shanghai, China; Gurugram, India; Heredia, Costa Rica and Galway, Ireland.
- Our Institutes for Advancing Science across the globe enable us to provide training for products and customers that are geared toward local needs and preferences, produced efficiently and informed by the insights of global thought leaders.
- We are expanding our global manufacturing network in order to increase our ability to address the needs of local physicians and patients, most recently opening one of our largest sites in Penang, Malaysia.
1 We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities in our Medical Devices business.
2 Non-GAAP measure; excludes certain GAAP items. For reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to our Financial Disclaimers and Non-GAAP Reconciliations.
3 Excludes Specialty Pharmaceuticals.
All trademarks are the property of their respective owners.